In VivoWhen Abbas Kazimi became CEO of Nimbus Therapeutics in March 2025, he didn’t need to introduce a sweeping new three-year vision. After 11 years at the company, having witnessed its evolution from a bo
ScripTakeda is already in launch preparations for oveporexton as the drug produced positive results in two Phase III trials in narcolepsy type 1 (NT1), making approval likely while also clearing the way fo
ScripThe market for BCMA-directed therapies to treat multiple myeloma just got a little more crowded with the US Food and Drug Administration giving the green light to Regeneron Pharmaceuticals’ Lynozyfic
ScripUnicycive has already identified a new manufacturing vendor, the company said, which could help it quickly resolve a complete response letter issued by the US Food and Drug Administration for oxylanth